Fluciclovine PET/CT scan for people with multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies how a special PET/CT scan (using fluciclovine) may help doctors evaluate multiple myeloma. You might be eligible if you’re a candidate for stem cell transplant (ASCT).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of multiple myeloma.
- Your doctor says you are suitable for ASCT treatment (stem cell transplant).
- You do not have any contraindications (reasons you cannot safely do ASCT).
- A study team member will review your medical history and transplant readiness to confirm eligibility.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
This Phase 1 trial tests a special PET scan tracer called 18F-fludarabine to help doctors better assess multiple myeloma at the start of treatment and right after treatment ends. The goal is to see how well this imaging tool can show disease activity so care can be tailored more accurately.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
This trial uses a special PET/MR scan with a radioactive tracer to help tell the difference between tumor regrowth and changes from radiation treatment in people with brain metastases. It may help doctors make better treatment decisions.
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.